PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
33.44 - 34.57
31.40 - 61.90
7.61M / 5.87M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.63%
Revenue growth at 50-75% of BRZE's 11.14%. Martin Whitman would worry about competitiveness or product relevance.
6.06%
Gross profit growth under 50% of BRZE's 13.94%. Michael Burry would be concerned about a severe competitive disadvantage.
4.87%
EBIT growth below 50% of BRZE's 11.46%. Michael Burry would suspect deeper competitive or cost structure issues.
4.87%
Operating income growth under 50% of BRZE's 11.46%. Michael Burry would be concerned about deeper cost or sales issues.
9.45%
Net income growth at 50-75% of BRZE's 15.69%. Martin Whitman would question fundamental disadvantages in expenses or demand.
7.14%
EPS growth under 50% of BRZE's 16.28%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
7.14%
Diluted EPS growth under 50% of BRZE's 16.67%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.88%
Share count expansion well above BRZE's 0.91%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.88%
Diluted share count expanding well above BRZE's 0.39%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
24.20%
Positive OCF growth while BRZE is negative. John Neff would see this as a clear operational advantage vs. the competitor.
27.27%
Positive FCF growth while BRZE is negative. John Neff would see a strong competitive edge in net cash generation.
-26.87%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-26.87%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-26.87%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
60.31%
Positive long-term OCF/share growth while BRZE is negative. John Neff would see a structural advantage in sustained cash generation.
60.31%
Positive OCF/share growth while BRZE is negative. John Neff might see a comparative advantage in operational cash viability.
60.31%
Positive 3Y OCF/share CAGR while BRZE is negative. John Neff might see a big short-term edge in operational efficiency.
1.38%
Net income/share CAGR at 50-75% of BRZE's 2.51%. Martin Whitman might question if the firm’s product or cost base lags behind.
1.38%
5Y net income/share CAGR at 50-75% of BRZE's 2.51%. Martin Whitman might see a shortfall in operational efficiency or brand power.
1.38%
3Y net income/share CAGR 50-75% of BRZE's 2.51%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.79%
Firm’s AR is declining while BRZE shows 12.45%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-6.99%
Inventory is declining while BRZE stands at 26.64%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.03%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-1.83%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
2.10%
R&D dropping or stable vs. BRZE's 7.94%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
1.53%
SG&A growth well above BRZE's 1.34%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.